Peripheral Artery Disease Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Ixaka Ltd, Hemostemix Inc., Caladrius Biosciences, Humacyte

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Peripheral Artery Disease pipeline constitutes 20+ key companies continuously working towards developing 22+ Peripheral Artery Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Peripheral Artery Disease Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Peripheral Artery Disease Market.

The Peripheral Artery Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Peripheral Artery Disease Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Peripheral Artery Disease treatment therapies with a considerable amount of success over the years.

*
Peripheral Artery Disease companies working in the treatment market are Ixaka Ltd (formerly known as Rexgenero), Hemostemix Inc., Caladrius Biosciences, Humacyte, Inc., Novo Nordisk, Helixmith, and others, are developing therapies for the Peripheral Artery Disease treatment

*
Emerging Peripheral Artery Disease therapies in the different phases of clinical trials are- REX-001, ACP-01, Honedra, Human Acellular Vessel (HAV), Semaglutide, VM202, and others are expected to have a significant impact on the Peripheral Artery Disease market in the coming years.

*
In June 2024, The U.S. Food and Drug Administration (FDA) has granted Amplitude Vascular Systems (AVS) an investigational device exemption (IDE), allowing the company to proceed with a pivotal trial for its pulsatile intravascular lithotripsy therapy. The POWER-PAD-II clinical study will assess the safety and effectiveness of AVS's Pulse IVL System in treating patients with severely calcified peripheral arterial disease.

*
In November 2024, R3 Vascular, a U.S.-based bioabsorbable scaffold company, has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the ELITE-BTK pivotal trial for its peripheral arterial disease (PAD) treatment.

*
In March 2024, BD (Becton, Dickinson and Company) (NYSE: BDX), a prominent global medical technology firm, announced today the enrollment of the first patient in the investigational device exemption (IDE) study titled "AGILITY." This study aims to evaluate the safety and effectiveness of the BD Vascular Covered Stent in treating Peripheral Arterial Disease (PAD).

*
In February 2024, Sensome has initiated the SEPARATE clinical trial to assess its Clotild Smart Guidewire technology for detecting blood vessel blockages in patients with peripheral artery disease (PAD). The Clotild device, which received breakthrough designation from the US Food and Drug Administration (FDA) in 2021 for brain artery applications, is now being evaluated for its potential benefits in PAD treatment.

Peripheral Artery Disease Overview

Peripheral Artery Disease (PAD) is a common circulatory condition characterized by the narrowing or blockage of the arteries outside the heart and brain, typically affecting the arteries in the legs. This reduction in blood flow can cause a range of symptoms and complications.

Get a Free Sample PDF Report to know more about Peripheral Artery Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight [https://www.delveinsight.com/report-store/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Peripheral Artery Disease Drugs Under Different Phases of Clinical Development Include:

*
REX-001: Ixaka Ltd (formerly known as Rexgenero)

*
ACP-01: Hemostemix Inc.

*
Honedra: Caladrius Biosciences

*
Human Acellular Vessel (HAV): Humacyte, Inc.

*
Semaglutide: Novo Nordisk

*
VM202: Helixmith

Peripheral Artery Disease Route of Administration

Peripheral Artery Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Peripheral Artery Disease Molecule Type

Peripheral Artery Disease Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Peripheral Artery Disease Pipeline Therapeutics Assessment

*
Peripheral Artery Disease Assessment by Product Type

*
Peripheral Artery Disease By Stage and Product Type

*
Peripheral Artery Disease Assessment by Route of Administration

*
Peripheral Artery Disease By Stage and Route of Administration

*
Peripheral Artery Disease Assessment by Molecule Type

*
Peripheral Artery Disease by Stage and Molecule Type

DelveInsight's Peripheral Artery Disease Report covers around 22+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Peripheral Artery Disease product details are provided in the report. Download the Peripheral Artery Disease pipeline report to learn more about the emerging Peripheral Artery Disease therapies [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Peripheral Artery Disease Therapeutics Market include:

Key companies developing therapies for Peripheral Artery Disease are - BIOTRONIK, Cardinal Health, Terumo Corporation, Bayer AG, Abbott, Boston Scientific Corporation, AngioDynamics, Koninklijke Philips NV, Cook, Medtronic, Cardinal Health, B. Braun Melsungen AG, and others.

Peripheral Artery Disease Pipeline Analysis:

The Peripheral Artery Disease pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral Artery Disease with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral Artery Disease Treatment.

*
Peripheral Artery Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Peripheral Artery Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral Artery Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Peripheral Artery Disease drugs and therapies [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Peripheral Artery Disease Pipeline Market Drivers

*
Increasing Prevalence of PAD, Technological Advancements, Growing Awareness, Government Initiatives, Improved Healthcare Infrastructure, Rising Healthcare Expenditure, Collaboration and Partnerships, Aging Population, are some of the important factors that are fueling the Peripheral Artery Disease Market.

Peripheral Artery Disease Pipeline Market Barriers

*
However, High Treatment Costs, Limited Awareness in Developing Regions, Regulatory Challenges, Economic Instability, Clinical Trial Challenges, Healthcare Infrastructure Gaps, and other factors are creating obstacles in the Peripheral Artery Disease Market growth.

Scope of Peripheral Artery Disease Pipeline Drug Insight

*
Coverage: Global

*
Key Peripheral Artery Disease Companies: Ixaka Ltd (formerly known as Rexgenero), Hemostemix Inc., Caladrius Biosciences, Humacyte, Inc., Novo Nordisk, Helixmith, and others

*
Key Peripheral Artery Disease Therapies: REX-001, ACP-01, Honedra, Human Acellular Vessel (HAV), Semaglutide, VM202, and others

*
Peripheral Artery Disease Therapeutic Assessment: Peripheral Artery Disease current marketed and Peripheral Artery Disease emerging therapies

*
Peripheral Artery Disease Market Dynamics: Peripheral Artery Disease market drivers and Peripheral Artery Disease market barriers

Request for Sample PDF Report for Peripheral Artery Disease Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Peripheral Artery Disease Report Introduction

2. Peripheral Artery Disease Executive Summary

3. Peripheral Artery Disease Overview

4. Peripheral Artery Disease- Analytical Perspective In-depth Commercial Assessment

5. Peripheral Artery Disease Pipeline Therapeutics

6. Peripheral Artery Disease Late Stage Products (Phase II/III)

7. Peripheral Artery Disease Mid Stage Products (Phase II)

8. Peripheral Artery Disease Early Stage Products (Phase I)

9. Peripheral Artery Disease Preclinical Stage Products

10. Peripheral Artery Disease Therapeutics Assessment

11. Peripheral Artery Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Peripheral Artery Disease Key Companies

14. Peripheral Artery Disease Key Products

15. Peripheral Artery Disease Unmet Needs

16 . Peripheral Artery Disease Market Drivers and Barriers

17. Peripheral Artery Disease Future Perspectives and Conclusion

18. Peripheral Artery Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peripheral-artery-disease-pipeline-2024-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-ixaka-ltd-hemostemix-inc-caladrius-biosciences-humacyte]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.